Priorities for improvement in health in patients with rheumatoid arthritis (RA) who are starting disease-modifying antirheumatic drugs (DMARDs), including biological agents

被引：0
|
作者：
Heiberg, T
Vinders, M
Olsen, CL
Magnussen, AS
Enersen, TB
Fekete, S
Kvien, TK
机构：
[1] Ullevaal Univ Hosp, Dept Adm, Oslo, Norway
[2] Lillehammer Hosp Rheumat Dis, Dept Rheumatol, Lillehammer, Norway
[3] Diakonhjemmet Hosp, Dept Rheumatol, Oslo, Norway
[4] St Olav Hosp, Dept Rheumatol, Trondheim, Norway
[5] Buskerud Cent Hosp, Dept Rheumatol, Drammen, Norway
[6] Univ Hosp No Norway, Dept Rheumatol, Tromso, Norway
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2004年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：558 / 558
页数：1
相关论文
共 50 条
  • [1] THE HEALTH AND ECONOMIC CONSEQUENCES OF DELAY IN STARTING DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) IN RHEUMATOID ARTHRITIS
    Van Doornum, S.
    Roberts, L.
    Reed, M. D.
    Liew, D.
    VALUE IN HEALTH, 2012, 15 (07) : A448 - A448
  • [2] THE HEALTH AND ECONOMIC CONSEQUENCES OF DELAY IN STARTING DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) IN RHEUMATOID ARTHRITIS
    Van Doornum, S.
    Franklyn, K.
    Tacey, M.
    Roberts, C.
    Liew, D.
    INTERNAL MEDICINE JOURNAL, 2013, 43 : 2 - 2
  • [3] EFFICIENCY OF NON-BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) IN RHEUMATOID ARTHRITIS (RA) PATIENTS WITH COMORBIDITY
    Mykytenko, G.
    Iaremenko, O.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 212 - 213
  • [4] The effect of disease-modifying antirheumatic drugs (DMARDs) on bone homeostasis in rheumatoid arthritis (RA) patients
    Khoshroo, Ahmadreza
    Ramezani, Keyvan
    Moghimi, Niusha
    Bonakdar, Moein
    Ramezani, Nazanin
    INFLAMMOPHARMACOLOGY, 2023, 31 (02) : 689 - 697
  • [5] The effect of disease-modifying antirheumatic drugs (DMARDs) on bone homeostasis in rheumatoid arthritis (RA) patients
    Ahmadreza Khoshroo
    Keyvan Ramezani
    Niusha Moghimi
    Moein Bonakdar
    Nazanin Ramezani
    Inflammopharmacology, 2023, 31 : 689 - 697
  • [6] Utilization of disease modifying antirheumatic drugs (DMARDs) among patients with rheumatoid arthritis (RA).
    MacLean, CH
    Park, GS
    Traina, SB
    Liu, HH
    Hahn, BH
    Paulus, HE
    Kahn, KI
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S143 - S143
  • [7] Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis
    Grijalva, Carlos G.
    Chung, Cecilia P.
    Arbogast, Patrick G.
    Stein, Charles M.
    Mitchel, Edward F., Jr.
    Griffin, Marie R.
    MEDICAL CARE, 2007, 45 (10) : S66 - S76
  • [8] Is there still a role for traditional disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis?
    Cannella, AC
    O'Dell, JR
    CURRENT OPINION IN RHEUMATOLOGY, 2003, 15 (03) : 185 - 192
  • [9] Predictors of Stopping and Starting Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis
    Solomon, Daniel H.
    Tonner, Chris
    Lu, Bing
    Kim, Seoyoung C.
    Ayanian, John Z.
    Brookhart, M. Alan
    Katz, Jeffrey N.
    Yelin, Ed
    ARTHRITIS CARE & RESEARCH, 2014, 66 (08) : 1152 - 1158
  • [10] Safety of biological disease-modifying antirheumatic drugs in rheumatoid arthritis
    Martinez-Mugica, Cristina
    Salgueiro, Esther
    FARMACIA HOSPITALARIA, 2022, 46 (01) : 15 - 20
12345